GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Matinas BioPharma
Shares of Matinas, a biopharmaceutical company, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials of its unique drug delivery technology.
Share prices of companies in the market segment - Pharma metabolism
Matinas BioPharma is a biopharmaceutical company developing drugs based on its platform for safe drug delivery, including antifungal and omega-3 agents. We've categorized it as a Pharmaceutical: Metabolism company. The chart below shows the dynamics in this sector.
Broad Market Index - GURU.Markets
Matinas BioPharma is a biopharmaceutical company that has developed a drug delivery platform that safely delivers drugs into cells. Its innovative technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Matinas compares to it.
Change in the price of a company, segment, and market as a whole per day
MTNB - Daily change in the company's share price Matinas BioPharma
For Matinas BioPharma Holdings, which develops a drug delivery platform, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Matinas BioPharma develops innovative drug delivery platforms aimed at treating infectious diseases and metabolic disorders. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing MTNB stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
Matinas BioPharma is a pharmaceutical company developing drugs to treat metabolic diseases. Its shares, like many in the sector, are volatile and react to news about clinical trials. These movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Matinas BioPharma
For Matinas BioPharma, year-over-year performance is a reflection of its unique drug delivery platform. Its 12-month market cap depends entirely on clinical trial data. Success in its LNC technology, which delivers antifungal drugs and omega-3 fatty acids, could be a breakthrough, but biotech carries high risks.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
As an early-stage biotech, Matinas is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drug delivery platform. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Matinas BioPharma is developing a unique drug delivery technology capable of improving the efficacy and safety of treatments. Its annual market capitalization dynamics reflect investor expectations for clinical trials and potential partnerships with major pharmaceutical companies. This is a story of how one technology can change the rules of the game.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Matinas BioPharma
Matinas is a biopharmaceutical company with a unique drug delivery platform. Its monthly performance is entirely dependent on the results of its clinical trials. News about its flagship programs are binary events for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company that has developed a unique platform for oral drug delivery. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its technology, which enables the delivery of complex molecules, including antibiotics and mRNA, in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Matinas BioPharma is a biotech company with a unique drug delivery technology. Its shares move on news of clinical trials and partnerships with major pharmaceutical companies. The chart shows the dynamics, which are determined entirely by the specifics of its scientific platform, rather than by general market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Matinas BioPharma
Matinas BioPharma develops a unique drug delivery technology that can make drugs more effective and safer. The company's weekly stock price has been a rollercoaster, driven by news of clinical trial results. The success or failure of a single study dramatically changes the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery technology aimed at combating infections and metabolic disorders. Its future course depends on research progress. The chart below shows how the company's weekly stock price fluctuates with overall movements in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Matinas BioPharma is a biotech company with a unique drug delivery technology. Its shares are steeped in clinical trials and scientific data. This chart demonstrates how its performance depends solely on internal news, not on overall market movements.
Market capitalization of the company, segment and market as a whole
MTNB - Market capitalization of the company Matinas BioPharma
Matinas BioPharma's market capitalization chart reflects investors' valuation of its unique drug delivery technology. Its dynamics reflect the market's belief that its lipid nanocrystal-based platform can make drugs safer and more effective. The company's valuation is a bet on a technology that can be applied to a wide range of drugs.
MTNB - Share of the company's market capitalization Matinas BioPharma within the market segment - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform that enables safe transport of drugs within the body. Its market share in the pharmaceutical sector is small, but it capitalizes on the potential of this technology. Its capitalization is a bet that its platform will improve existing drugs.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total market capitalization of the entire biotech sector focused on treating metabolic and infectious diseases. For Matinas BioPharma, with its unique drug delivery platform, this line demonstrates the scale of the market. The rising chart reflects the need for new, safer, and more effective ways to deliver drugs into cells.
Market capitalization of all companies included in a broad market index - GURU.Markets
Matinas BioPharma is developing a unique drug delivery technology capable of packaging drugs in safe nanocrystals. Its market capitalization is the valuation of this platform. This represents the market share of innovations in drug delivery methods.
Book value capitalization of the company, segment and market as a whole
MTNB - Book value capitalization of the company Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery platform. Its book value is the sum of its financial resources and intellectual property. This consists of cash flow for clinical trials and the value of patents. How has this scientific capital changed? The chart below shows.
MTNB - Share of the company's book capitalization Matinas BioPharma within the market segment - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform. Its technology requires its own facilities: a laboratory for creating and testing its lipid nanocrystals (LNCs). The chart shows the company's share of the physical R&D infrastructure for developing new drug delivery systems.
Market segment balance sheet capitalization - Pharma metabolism
Matinas BioPharma is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Matinas focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Matinas BioPharma's book value is not derived from its plants, but from its unique drug delivery platform (LNC), which enables the safe transport of complex molecules into cells. Its assets reflect the scientific potential and capital for developing this promising technology. The chart illustrates its scale in the biotech world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery technology. Its market capitalization is the valuation of its platform, which promises to make drugs more effective and safer. Investors are betting on this technology, not on their current tangible assets.
Market to book capitalization ratio in a market segment - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform. Its high valuation on this chart is not a valuation of its current assets, but rather a bet by investors that its technology will make other drugs more effective and safer, opening up a huge market opportunity.
Market to book capitalization ratio for the market as a whole
Matinas BioPharma develops innovative drug delivery platforms. The company's value is determined by its intellectual property and potential to transform treatment approaches. This chart shows the market premium for cutting-edge scientific developments that may not yet generate revenue but hold enormous promise.
Debts of the company, segment and market as a whole
MTNB - Company debts Matinas BioPharma
Matinas BioPharma, a biopharmaceutical company with a unique drug delivery technology, uses raised capital to fund its clinical programs. This chart shows how the company invests in proving the effectiveness of its platform, which requires significant and risky R&D before any revenue is realized.
Market segment debts - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform that enables safe delivery of drugs into cells. This graph illustrates how a clinical-stage biotech company is funding the development of its breakthrough, yet unproven, technology, a classic model for innovative biotech.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery platform that enables the safe delivery of antifungal and other drugs. Clinical trials of this new technology require significant investment. This chart shows how the company is using debt to finance its high-risk, yet potentially valuable, developments.
Market segment debt to market segment book capitalization - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform that could make drugs safer and more effective. This chart shows how the biotech startup is funding its preclinical and clinical research, comparing its debt structure to the overall financial landscape in the capital-intensive biotech sector.
Debt to book value of all companies in the market
Matinas BioPharma is developing an innovative drug delivery platform that could make drugs more effective and safer. Biotechnology requires enormous investment. How heavily does the company rely on debt to fund its research? This chart of total debt in the economy provides context for assessing its financial sustainability.
P/E of the company, segment and market as a whole
P/E - Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company developing a unique drug delivery platform that enables safe delivery of drugs into cells. This chart shows how investors value its technology. The valuation is volatile and depends on the results of clinical trials of its candidates.
P/E of the market segment - Pharma metabolism
Matinas BioPharma is a biopharmaceutical company developing a drug delivery platform that enables the safe delivery of various therapeutic agents, including antifungal and antiviral drugs. This chart illustrates the average valuation in the pharmaceutical sector, which values innovative platforms that can improve existing drugs.
P/E of the market as a whole
Matinas BioPharma is developing an innovative drug delivery platform that enables the encapsulation of various drugs to improve their tolerability and efficacy. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether MTNB's valuation is based on faith in its unique technology platform or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery platform that enables safe transport of drugs within cells. This could solve the toxicity issues of many drugs. This chart reflects investors' confidence in the potential of this technology and its ability to lead to new, more effective treatments.
%20P%2FE%20Matinas%20BioPharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Matinas-BioPharma&v=1772627981039 "Chart of the company's future (projected) P/E Matinas BioPharma")
Future (projected) P/E of the market segment - Pharma metabolism
Matinas BioPharma is developing a unique drug delivery platform that could make drugs safer and more effective. The chart shows average profitability expectations in the pharmaceutical sector. It helps understand how highly the market values this technology's potential for creating new therapeutics and future partnerships.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772627981049 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Matinas BioPharma is developing a unique drug delivery technology that enables the safe transport of drugs within cells. This platform offers significant potential. This market sentiment chart reflects the investor appetite for biotech platforms that could yield a whole new class of drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772627981065 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery platform that enables the safe transport of active substances within the body. Financial indicators reflect research expenditures. This chart shows investments in a technology that could address toxicity and efficacy issues for a wide range of drugs and generate significant profits.
Profit of companies in the market segment - Pharma metabolism
Matinas BioPharma is developing an innovative drug delivery platform that enables the safe delivery of antifungal and other drugs into cells. This chart illustrates the overall profitability of the pharmaceutical sector, where new delivery technologies can improve the efficacy of existing drugs and reduce their toxicity, opening up new therapeutic opportunities.
Overall market profit
Matinas BioPharma develops innovative drug delivery platforms, including for the treatment of infectious diseases. The company's future depends on the success of its clinical programs and partnerships with major pharmaceutical companies. This process is independent of the general economic cycles shown in the chart, which is typical for the biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Matinas BioPharma
Matinas BioPharma is developing a drug delivery platform that enables the safe delivery of antifungal and other drugs into cells. Future revenue depends on the success of clinical trials and partnerships with major pharmaceutical companies. This chart reflects analyst expectations regarding the commercial potential of this innovative technology.
%20profit%20of%20the%20company%20Matinas%20BioPharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Matinas-BioPharma&v=1772627981210 "Graph of future (projected) profit of the company Matinas BioPharma")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Matinas BioPharma is developing an innovative drug delivery platform that enables the safe transport of drugs within the body. The company is applying this technology to the treatment of fungal infections and metabolic diseases. This chart shows revenue projections for the pharmaceutical sector, providing context for assessing the potential of Matinas' platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772627981322 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Matinas BioPharma is a biopharmaceutical company developing innovative drug delivery platforms. Its future depends on successful clinical trials and partnerships. This economic outlook affects the availability of venture capital and the willingness of large pharmaceutical companies to invest in biotechnology.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772627981377 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Matinas BioPharma
Matinas BioPharma is developing a unique drug delivery platform capable of combating serious infections. While the company is in the clinical stage, it may not have stable revenue. This chart reflects investor valuation of the technology itself. Its significance reflects the bet that the platform will prove effective and lead to blockbuster development.
P/S market segment - Pharma metabolism
Matinas BioPharma develops innovative drugs for the treatment of severe fungal infections and cardiovascular diseases using its unique lipid nanocrystal (LNC) drug delivery platform. This chart displays the average revenue estimate for the sector, providing insight into the market's perception of the potential of this cutting-edge pharmaceutical technology.
P/S of the market as a whole
Matinas BioPharma develops an innovative drug delivery platform that enables the safe delivery of antifungal and other medications. This chart highlights that the valuation of such biotech companies depends not on current revenue, but on the potential of their technology platform to transform treatment standards, which stands in stark contrast to the market average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Matinas BioPharma
Matinas BioPharma is developing a drug delivery platform that enables encapsulation of drugs to improve their safety and efficacy profiles. For a biotech company like this, estimating future revenue is critical. It reflects investors' confidence in the potential of this technology and the future success of its drug candidates in treating infectious diseases and other conditions.
%20P%2FS%20Matinas%20BioPharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Matinas-BioPharma&v=1772627981592 "The graph of the company's future (projected) P/S Matinas BioPharma")
Future (projected) P/S of the market segment - Pharma metabolism
Matinas BioPharma is developing a drug delivery platform that enables the encapsulation of various drugs to improve their safety and efficacy profiles. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the potential of its LNC technology for developing new treatments for infectious and metabolic diseases.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772627981622 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Matinas BioPharma is developing a unique drug delivery platform that enables the safe transport of drugs within the body. The company's future depends on the success of its clinical programs. This market outlook chart reflects investor confidence that innovative drug delivery methods can dramatically improve existing therapies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772627981662 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Matinas BioPharma
For Matinas BioPharma, this figure reflects revenues, which at this stage likely consist of collaboration fees rather than sales of its own products. The company develops innovative drug delivery platforms. Future revenue will depend on successful clinical trials and commercialization of its developments.
Sales of companies in the market segment - Pharma metabolism
Matinas BioPharma develops innovative drug delivery platforms. Its revenue currently consists of partnerships with major pharmaceutical companies. Its future sales structure will depend on the success of its own candidates, demonstrating its dual strategy: partnerships and independent development.
Overall market sales
Matinas BioPharma develops innovative drug delivery platforms, aiming to improve their efficacy and safety. The company's success depends on the results of clinical trials and partnerships with major pharmaceutical companies. This general economics chart is not directly related to the company, whose value lies in breakthrough scientific technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Matinas BioPharma
Matinas BioPharma is developing an innovative drug delivery platform that enables the safe delivery of various therapeutic agents, including antifungals and omega-3 fatty acids. Future revenues are dependent on the success of clinical trials. This graph reflects analyst expectations for the commercial potential of its technology and development pipeline.
%20sales%20of%20the%20company%20Matinas%20BioPharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Matinas-BioPharma&v=1772627981837 "Schedule of future (projected) sales of the company Matinas BioPharma")
Future (projected) sales of companies in the market segment - Pharma metabolism
Matinas BioPharma is developing an innovative drug delivery platform capable of overcoming barriers in the body. This chart shows sales forecasts for the biotech sector. Is demand growing for new delivery technologies that can improve drug efficacy and safety? This reflects a general trend in the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772627981895 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Matinas BioPharma is a biopharmaceutical company developing drugs to treat metabolic and infectious diseases. Its success is determined by clinical trial results and regulatory approvals, not by the economic outlook. This chart, which reflects consumer spending, is not directly related to the company's fundamental growth drivers.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772627981918 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Matinas BioPharma
Matinas BioPharma is developing an innovative drug delivery platform that enables safe transport of drugs within the body. This chart reflects its financial performance at the clinical trial stage. Profitability is a future goal, which will depend on the successful application of its technology to create new, more effective, and safer drugs.
Market segment marginality - Pharma metabolism
Matinas BioPharma is a biopharmaceutical company developing a unique drug delivery platform that enables safe delivery of drugs into cells. This chart reflects the company's financial performance at the R&D stage, where future profitability depends on the success of clinical trials and partnerships with major pharmaceutical companies.
Market marginality as a whole
Matinas BioPharma, developing innovative drug delivery platforms, aims to address the toxicity and efficacy issues of existing therapies. Its success depends on long-term funding. This gross profitability chart reflects the investment climate and market willingness to invest in high-potential biotech innovations.
Employees in the company, segment and market as a whole
Number of employees in the company Matinas BioPharma
Matinas BioPharma develops a unique drug delivery platform that enables safe transport of drugs within the body. Its small team of scientists is its greatest asset. This chart shows how the company manages its resources during clinical trials, where even a small increase in staff can mean significant progress.
Share of the company's employees Matinas BioPharma within the market segment - Pharma metabolism
Matinas BioPharma is developing an innovative drug delivery platform that could improve the efficacy and safety of therapeutics. Its work is focused on laboratories and requires a team of chemists and biologists. This chart shows the company's share of the biotech labor market, reflecting its focus on R&D and the scale of its scientific research program.
Number of employees in the market segment - Pharma metabolism
Matinas BioPharma is developing a lipid nanocrystal-based drug delivery platform that enables safe intracellular delivery of drugs. The chart illustrates the company's work in the metabolic pharmaceuticals sector. Matinas' innovative delivery technology can be applied to various drug classes, addressing toxicity and efficacy issues.
Number of employees in the market as a whole
Matinas BioPharma develops innovative drug delivery platforms, particularly for the treatment of fungal infections. Its development depends on success in clinical trials. Given the overall labor market dynamics reflected in this graph, Matinas exemplifies a biotech company where every new hire brings new treatments closer.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Matinas BioPharma (MTNB)
Matinas BioPharma is a biotech company with a unique drug delivery platform, LNC (lipid nanocrystals). Their entire current value stems from the potential of this technology. This graph shows the market premium placed on their R&D. It reflects the market value per employee, which is a direct measure of the intellectual capital of their research team.
%20of%20the%20company%20Matinas%20BioPharma%20(MTNB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Matinas-BioPharma-MTNB&v=1772627982325 "Chart of market capitalization per employee (in thousands of dollars) of the company Matinas BioPharma (MTNB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Matinas BioPharma (MTNB) is developing a unique drug delivery platform that enables safe delivery of drugs to their target. In biotech, this metric evaluates the breakthrough potential of a technology. The very high market capitalization per employee suggests that the LNC platform has the potential to transform the treatment of many diseases, which is what investors value.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772627982415 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Matinas BioPharma is developing a unique drug delivery platform that enables safe delivery of drugs into cells. The company's valuation is based on the potential of this technology. The chart shows a high valuation per employee, as the market believes this platform can be applied to many drugs, creating enormous value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772627982526 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Matinas BioPharma (MTNB)
Matinas BioPharma is a biotech company developing a unique drug delivery platform. Like many clinical-stage companies, this graph likely shows a loss per employee. It reflects the intensity of R&D: every scientist is an investment in a technology that hasn't yet reached the market and isn't generating revenue.
%20Chart%20Matinas%20BioPharma%20(MTNB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Matinas-BioPharma-MTNB&v=1772627982567 "Company Profit Per Employee (in thousands of dollars) Chart Matinas BioPharma (MTNB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Matinas BioPharma develops innovative drug delivery platforms, particularly for the treatment of metabolic disorders. In biotech, team effectiveness is often more important than team size. This graph illustrates the value each employee generates, allowing one to assess the commercial potential of their technology and compare it with other pharmaceutical companies in the development stage.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772627982640 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Matinas BioPharma is a biotech company developing a unique lipid nanocrystal (LNC) platform for drug delivery. It's an R&D company, where all capital is invested in science. This chart, showing the average profitability per employee across the market, highlights the contrast with biotech, where staffing is minimal, but the potential value (or loss) per scientist is enormous.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772627982680 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Matinas BioPharma (MTNB)
Matinas BioPharma develops innovative drug delivery platforms. As with many clinical-stage biotechs, current revenue per employee can be low. The chart illustrates the potential: a successful delivery technology could be licensed to giants, resulting in massive revenue with a small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Matinas-BioPharma-MTNB&v=1772627982704 "Sales chart per company employee Matinas BioPharma (MTNB)")
Sales per employee in the market segment - Pharma metabolism
Matinas BioPharma is a clinical-stage biotech developing a unique platform (LNC) for intracellular drug delivery (including antifungal agents). They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of Matinas' R&D staffing efficiency compared to other biotechs.
Sales per employee for the market as a whole
Matinas BioPharma is developing a unique drug delivery technology (LNC) capable of encapsulating complex drugs. Currently, their business is focused on R&D and partnerships. This graph reflects their research phase: revenue, if any (from partnerships), is generated not by mass sales, but by the work of their research team.
Short shares by company, segment and market as a whole
Shares shorted by company Matinas BioPharma (MTNB)
Matinas BioPharma (MTNB) is developing a drug delivery platform (including antifungals) that it claims is less toxic. This chart tracks bearish bets. The shorts reflect market skepticism: investors may believe that clinical trials will not prove the superiority of this delivery technology over existing drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Matinas-BioPharma-MTNB&v=1772627982858 "Short Shares Chart for the Company Matinas BioPharma (MTNB)")
Shares shorted by market segment - Pharma metabolism
Matinas BioPharma (MTNB) is developing a drug delivery platform (LNC) that enables the safe delivery of complex molecules (such as antifungals) into cells. This chart aggregates short positions across the biotech sector. It reflects investor skepticism about new drug delivery platforms until they generate decisive clinical data.
Shares shorted by the overall market
Matinas (MTNB) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like MTNB in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Matinas BioPharma (MTNB)
Matinas BioPharma (MTNB) develops a unique drug delivery platform (LNC) that enables the safe delivery of complex molecules, including antifungal drugs. This indicator measures the rate of price change. It helps identify when investor enthusiasm (above 70) or disappointment (below 30) about clinical trial data peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Matinas-BioPharma-MTNB&v=1772627982926 "RSI 14 indicator chart for the company's stock Matinas BioPharma (MTNB)")
RSI 14 Market Segment - Pharma metabolism
Matinas BioPharma is a biopharmaceutical company with a unique LNC drug delivery platform. It enables the oral delivery of complex molecules (including RNA) into cells. This chart shows the overall sentiment in the biotech sector focused on drug metabolism and delivery. It helps differentiate MTNB's performance from the broader trend sweeping the industry.
RSI 14 for the overall market
Matinas BioPharma (MTNB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MTNB (Matinas BioPharma)
Matinas BioPharma is developing a unique platform (LNC) for the oral delivery of complex drugs, including mRNA and antifungals. This chart shows the average analyst forecast. Their targets are based on an assessment of clinical data for its lead candidates and the potential of this breakthrough delivery technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MTNB-Matinas-BioPharma&v=1772627982953 "A chart showing analyst consensus forecasts for the expected stock price. MTNB (Matinas BioPharma)")
The difference between the consensus estimate and the actual stock price MTNB (Matinas BioPharma)
Matinas BioPharma is a biotech company with a unique LNC platform that encapsulates drugs in lipid nanocrystals, making them safer and more effective. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this drug delivery technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MTNB-Matinas-BioPharma&v=1772627983055 "A chart showing the difference between the consensus forecast and the actual stock price. MTNB (Matinas BioPharma)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Matinas BioPharma is a biotech company developing a "smart" capsule (LNC) that delivers drugs (including omega-3) to the lymphatic system. This chart shows general expectations for the metabolism sector. It reflects whether experts believe in the success of new R&D drug delivery platforms.
Analysts' consensus forecast for the overall market share price
Matinas BioPharma (MTNB) is a biopharmaceutical company with a unique delivery system. They have developed lipid nanocrystals (LNCs) that are designed to safely deliver RNA drugs and antibiotics into cells. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but high-risk R&D platforms.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Matinas BioPharma
Matinas BioPharma is a drug smuggler. Their signature product is LNC, a lipid nanocrystalline platform (like a fat sac) that (they claim) can safely deliver toxic drugs (antifungals, RNA) into cells. This graph is a clear indicator of their R&D. It reflects their (very long) journey and the market's faith in their delivery system.
AKIMA Market Segment Index - Pharma metabolism
Matinas BioPharma (MTNB) is solving the problem of drug delivery. Their LNC (lipid nanocrystal) platform enables the safe packaging of toxic yet effective drugs (such as antifungals) and their oral delivery. This chart shows the average index for the segment, helping to assess how this platform technology compares to the average.
The AKIM Index for the overall market
Matinas BioPharma is a biopharmaceutical company that has developed a lipid nanocrystal (LNC) platform for drug delivery. The technology reduces toxicity. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative delivery platform compares to overall economic trends and partner interest.
